Autolus Therapeutics (NASDAQ:AUTL) Trading Up 16.1% – What’s Next?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shot up 16.1% during mid-day trading on Monday . The company traded as high as $1.8350 and last traded at $1.8920. 873,891 shares were traded during trading, a decline of 49% from the average session volume of 1,728,245 shares. The stock had previously closed at $1.63.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AUTL. Truist Financial upgraded Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. HC Wainwright lifted their price target on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Finally, Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Autolus Therapeutics Stock Up 15.0%

The stock has a market capitalization of $499.01 million, a P/E ratio of -1.72 and a beta of 1.93. The company has a 50 day moving average of $1.48 and a 200-day moving average of $1.51.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. Equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. Independent Advisor Alliance bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $28,000. Marex Group plc bought a new position in Autolus Therapeutics during the 2nd quarter worth $28,000. Waverly Advisors LLC acquired a new stake in Autolus Therapeutics in the first quarter worth $37,000. SmartHarvest Portfolios LLC acquired a new stake in Autolus Therapeutics in the fourth quarter worth $43,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Autolus Therapeutics in the third quarter valued at $46,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.